November 16, 2012

Sanofi Receives Positive CHMP Opinion in the European Union for Once-Daily Lyxumia® (lixisenatide)

- Diabetes portfolio poised to significantly expand in 2013 to meet patient needs -

 

Sanofi Receives Positive CHMP Opinion in the European Union for Once-Daily Lyxumia® (lixisenatide)
- Diabetes portfolio poised to significantly expand in 2013 to meet patient needs -

Paris, France – November 16, 2012 – Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of once-daily Lyxumia® (lixisenatide) for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control. The CHMP positive opinion will now be forwarded to the European Commission (EC), which has the authority to approve medicines for the European Union. Following EC marketing authorization, which is typically granted 2–3 months after a positive opinion, Lyxumia will significantly expand the company’s diabetes franchise.